Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Immutep Ltd ( (AU:IMM) ) is now available.
UBS Group AG and its related entities have notified Immutep Ltd that they have ceased to be a substantial shareholder in the company as of 16 March 2026, following changes in their relevant interests in Immutep’s voting securities. The change in UBS’s holding may alter Immutep’s institutional investor base and could signal a shift in the company’s shareholder dynamics, although no details were provided on the underlying reasons or any associated strategic implications.
The notice records that UBS’s prior substantial holding disclosure was lodged in mid-March 2026 and that subsequent transactions, detailed in an appendix to the filing, reduced its interest below the substantial holder threshold. While the filing is largely procedural, such movements by a major financial institution can be closely watched by the market as an indicator of evolving sentiment toward Immutep’s prospects and risk profile.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments, particularly in the field of cancer and immune modulation. The company operates in the life sciences sector and its activities center on advancing clinical programs that leverage the LAG-3 immune control mechanism to address significant unmet medical needs.
Average Trading Volume: 16,965,718
Technical Sentiment Signal: Sell
Current Market Cap: A$75.16M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.